ALXO — ALX Oncology Holdings Inc.

Summary of ALX Oncology Holdings Inc. Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Cash Position: As of December 31, 2025, ALX had cash, cash equivalents, and investments totaling $48.3 million. Following a recent equity financing, net proceeds were $140.4 million, providing sufficient funding through 2028.
• Net Loss: The GAAP net loss for Q4 2025 was $22.8 million ($0.42 per share), a decrease from a net loss of $29.2 million ($0.55 per share) in Q4 2024, attributed to lower stock compensation and operational costs.

2. Strategic Updates and Business Highlights

• Leadership: Barbara Klencke was appointed as the permanent Chief Medical Officer, having previously served in an interim capacity since September 2025.
• Clinical Programs:
  • Evorpocept (EVO): Over 750 patients treated, with promising data from HER2-positive gastric cancer and breast cancer trials. The drug shows potential as a first-in-class treatment targeting CD47 expression.
  • ALX 2004: A novel EGFR-targeted antibody-drug conjugate (ADC) is progressing through dose escalation, with safety data expected in the second half of 2026.
• Financing: The successful completion of a $150 million financing strengthens the company’s ability to advance its clinical programs.

3. Forward Guidance and Outlook

• Clinical Milestones:
  • Full biomarker analysis from the phase 1/2 trial of EVO is expected at the ESMO Breast Conference in May 2026.
  • Safety data for ALX 2004 anticipated in late 2026.
  • Top-line data from 80 patients in the ongoing phase 2 ASPEN-9 breast cancer trial is projected for mid-2027.
• Patient Enrollment: The ASPEN-9 trial is expanding from 80 to 120 patients to ensure robust data on CD47 expression.

4. Bad News, Challenges, or Points of Concern

• Clinical Risks: Although the company is optimistic about its data, the reliance on CD47 as a predictive biomarker poses regulatory risks if the anticipated outcomes do not materialize.
• Market Competition: The evolving treatment landscape for breast cancer, particularly post-in-HER2 therapies, presents challenges as new therapies may impact patient responses and market dynamics.
• Operational Execution: While the company has made significant progress, maintaining execution and meeting timelines for clinical trials remains critical.

5. Notable Q&A Insights

• EVO Trial Size and Endpoint: The decision to increase the ASPEN-9 trial size was driven by the need for robust data on CD47 expression, with a focus on ensuring sufficient numbers of patients with high CD47 levels.
• Investigator Feedback: Investigators are enthusiastic about the biomarker-driven approach, seeing it as a way to identify patients who would benefit most from treatment.
• Monitoring Safety: For ALX 2004, the company is implementing rigorous monitoring protocols for potential interstitial lung disease and skin toxicity, with confidence stemming from preclinical studies showing low toxicity.

Overall, ALX Oncology is positioned for significant developments in its clinical programs, with a focus on executing its strategies effectively while navigating potential challenges in the competitive oncology landscape.